Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Latanoprostene Bunod on EVP and Outflow Facility in OHT
NCT04140279Phase 4Withdrawn
- Sponsor
- Bausch + Lomb
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of latanoprostene bunod in ocular hypertension, sponsored by Bausch + Lomb. Planned start May 2022; status: withdrawn.
02
Drugs
latanoprostene bunod
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT04140279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140279.